Otavio Rizzi Coelho Filho

Otavio Rizzi Coelho Filho

Auto-generated profile, based on publicly available information

Otavio Rizzi Coelho Filho

Faculdade de Ciências Médicas, Universidade Estadual de Campinas, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2010 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
CHCarolyn Y. Ho
Carolyn Y. Ho
BLBegoña López
Begoña López
OCOtavio R. Coelho-Filho
Otavio R. Coelho-Filho
NLNeal K. Lakdawala
Neal K. Lakdawala
ACAllison L. Cirino
Allison L. Cirino
CSChristine E. Seidman
Christine E. Seidman
Myocardial fibrosis is a hallmark of hypertrophic cardiomyopathy and a proposed substrate for arrhythmias and heart failure. In animal models, profibrotic genetic pathways are activated early, before hypertrophic remodeling. Data showing early profibrotic responses to sarcomere-gene mutations in patients with hypertrophic cardiomyopathy are lacking. We used echocardiography, cardiac magnetic resonance imaging (MRI), and serum biomarkers of collagen metabolism, hemodynamic stress, and myocardial injury to evaluate subjects with hypertrophic cardiomyopathy and a confirmed genotype. The study involved 38 subjects with pathogenic sarcomere mutations and overt hypertrophic cardiomyopathy, 39 subjects with mutations but no left ventricular hypertrophy, and 30 controls who did not have mutations. Levels of serum C-terminal propeptide of type I procollagen (PICP) were significantly higher in mutation carriers without left ventricular hypertrophy and in subjects with overt hypertrophic cardiomyopathy than in controls (31% and 69% higher, respectively; P<0.001). The ratio of PICP to C-terminal telopeptide of type I collagen was increased only in subjects with overt hypertrophic cardiomyopathy, suggesting that collagen synthesis exceeds degradation. Cardiac MRI studies showed late gadolinium enhancement, indicating myocardial fibrosis, in 71% of subjects with overt hypertrophic cardiomyopathy but in none of the mutation carriers without left ventricular hypertrophy. Elevated levels of serum PICP indicated increased myocardial collagen synthesis in sarcomere-mutation carriers without overt disease. This profibrotic state preceded the development of left ventricular hypertrophy or fibrosis visible on MRI. (Funded by the National Institutes of Health and others.)

7 May 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
LZLili Zhang
Lili Zhang
MAMagid Awadalla
Magid Awadalla
SMSyed S Mahmood
Syed S Mahmood
ANAnju Nohria
Anju Nohria
MHMalek Hassan
Malek Hassan
TNTomas G Neilan
Tomas G Neilan
Aims: Myocarditis is a potentially fatal complication of immune checkpoint inhibitors (ICI). Sparse data exist on the use of cardiovascular magnetic resonance (CMR) in ICI-associated myocarditis. In this study, the CMR characteristics and the association between CMR features and cardiovascular events among patients with ICI-associated myocarditis are presented. Methods and results: From an international registry of patients with ICI-associated myocarditis, clinical, CMR, and histopathological findings were collected. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block. In 103 patients diagnosed with ICI-associated myocarditis who had a CMR, the mean left ventricular ejection fraction (LVEF) was 50%, and 61% of patients had an LVEF ≥50%. Late gadolinium enhancement (LGE) was present in 48% overall, 55% of the reduced EF, and 43% of the preserved EF cohort. Elevated T2-weighted short tau inversion recovery (STIR) was present in 28% overall, 30% of the reduced EF, and 26% of the preserved EF cohort. The presence of LGE increased from 21.6%, when CMR was performed within 4 days of admission to 72.0% when CMR was performed on Day 4 of admission or later. Fifty-six patients had cardiac pathology. Late gadolinium enhancement was present in 35% of patients with pathological fibrosis and elevated T2-weighted STIR signal was present in 26% with a lymphocytic infiltration. Forty-one patients (40%) had MACE over a follow-up time of 5 months. The presence of LGE, LGE pattern, or elevated T2-weighted STIR were not associated with MACE. Conclusion: These data suggest caution in reliance on LGE or a qualitative T2-STIR-only approach for the exclusion of ICI-associated myocarditis.

1 January 2019 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
DPDalton Bertolim Précoma
Dalton Bertolim Précoma
GOGláucia Maria Moraes De Oliveira
Gláucia Maria Moraes De Oliveira
ASAntonio Felipe Simão
Antonio Felipe Simão
ODOscar Pereira Dutra
Oscar Pereira Dutra
OCOtávio Rizzi Coelho
Otávio Rizzi Coelho
RMRicardo Mourilhe-Rocha
Ricardo Mourilhe-Rocha

1 December 2012 in The American Journal of Cardiology
Verified
Journal Article
Closed access
TNTomas G. Neilan
Tomas G. Neilan
OCOtavio R. Coelho-Filho
Otavio R. Coelho-Filho
DPDiego Pena-Herrera
Diego Pena-Herrera
RSRavi V. Shah
Ravi V. Shah
MJMichael Jerosch-Herold
Michael Jerosch-Herold
RKRaymond Y. Kwong
Raymond Y. Kwong

1 September 2013 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
TNTomas G. Neilan
Tomas G. Neilan
OCOtavio R. Coelho-Filho
Otavio R. Coelho-Filho
SDStephan B. Danik
Stephan B. Danik
RSRavi V. Shah
Ravi V. Shah
JDJohn A. Dodson
John A. Dodson
RKRaymond Y. Kwong
Raymond Y. Kwong

1 March 2013 in The American Journal of Cardiology
Verified
Journal Article
Closed access
TNTomas G. Neilan
Tomas G. Neilan
OCOtavio R. Coelho-Filho
Otavio R. Coelho-Filho
RSRavi V. Shah
Ravi V. Shah
JFJiazuo H. Feng
Jiazuo H. Feng
DPDiego Pena-Herrera
Diego Pena-Herrera
MJMichael Jerosch-Herold
Michael Jerosch-Herold